Qiagen NV has received an expanded PMA indication for its Therascreen diagnostic test to be used in conjunction with Boehringer Ingleheim GmbH's lung cancer therapy, Gilotrif (afatinib). The approval extends the labeling claim to include detection of EGFR mutations L681Q, G719X and S768I to aid the identification of metastatic non-smal-cell lung cancer (NSCLC) patients for whom Gilotrif is indicated. Read More
